Table 1.
Baseline characteristics of included patients with ovarian cancer (n=52,182)
| Patient Characteristics | Total N=52,182 |
With previous malignancy N=1,860 (3.6%) |
No previous malignancy N=50,322 (96.4%) |
p | ||
|---|---|---|---|---|---|---|
| Age at diagnosis | <0.001 | |||||
| 18-40 | 65 | (3.5%) | 4,298 (8.5%) | |||
| 41-65 | 818 | (44.0%) | 26,071 (51.8%) | |||
| >65 | 977 | (52.5%) | 1,938 (39.7%) | |||
| Year of diagnosis | 0.887 | |||||
| 2004-2009 | 912 | (49.0%) | 24,589 | (48.9%) | ||
| 2010-2015 | 948 | (51.0%) | 25,733 | (51.1%) | ||
| Race | 0.002 | |||||
| White | 1,565 | (84.1%) | 41,268 | (82.0%) | ||
| Black | 156 | (8.4%) | 4,260 | (8.5%) | ||
| AI/AN | 15 | (0.8%) | 341 | (0.7%) | ||
| AP | 124 | (6.7%) | 4,220 | (8.4%) | ||
| Unknown | 0 | (0.0%) | 233 | (0.5%) | ||
| CA-125 | <0.001 | |||||
| Elevated | 1,061 | (57.0%) | 33,437 | (66.4%) | ||
| Normal | 182 | (9.8%) | 4,183 | (8.3%) | ||
| Unknown | 617 | (33.2%) | 12,702 | (25.2%) | ||
| Histologic Type | <0.001 | |||||
| Epithelial | 1,207 | (64.9%) | 33,758 | (67.1%) | ||
| Sex-cord-stromal | 25 | (1.3%) | 970 | (1.9%) | ||
| Germ-cell | 4 | (0.2%) | 1,061 | (2.1%) | ||
| Others | 624 | (33.5%) | 14,533 | (28.9%) | ||
| Tumour Size | <0.001 | |||||
| 0-1 mm | 77 | (4.1%) | 1,713 | (3.4%) | ||
| 1-5 mm | 254 | (13.7%) | 5,680 | (11.3%) | ||
| 5-10 mm | 382 | (20.5%) | 9,770 | (19.4%) | ||
| 10-20 mm | 367 | (19.7%) | 12,343 | (24.5%) | ||
| >20 mm | 69 | (3.7%) | 3,051 | (6.1%) | ||
| Unknown | 711 | (38.2%) | 17,765 | (35.3%) | ||
| AJCC stage (6th) | <0.001 | |||||
| I | 373 | (20.1%) | 10,494 | (20.9%) | ||
| II | 166 | (8.9%) | 3,575 | (7.1%) | ||
| III | 475 | (25.5%) | 14,221 | (28.3%) | ||
| IV | 476 | (25.6%) | 13,740 | (27.3%) | ||
| Others | 370 | (19.9%) | 8,292 | (16.5%) | ||
| Grade | 0.310 | |||||
| I | 109 | (5.9%) | 3,236 | (6.4%) | ||
| II | 193 | (10.4%) | 5,692 | (11.3%) | ||
| III | 554 | (29.8%) | 15,435 | (30.7%) | ||
| IV | 331 | (16.7%) | 8,112 | (16.1%) | ||
| V | 693 | (37.3%) | 17,847 | (35.5%) | ||
| Surgery | <0.001 | |||||
| Yes | 1,399 | (75.2%) | 40,023 | (79.5%) | ||
| No | 452 | (24.3%) | 9,976 | (19.8%) | ||
| Unknown | 9 | (0.5%) | 323 | (0.6%) | ||
| Radiation | 0.129 | |||||
| Yes | 25 | (1.3%) | 496 | (1.0%) | ||
| No | 1,833 | (98.5%) | 49,805 | (99.0%) | ||
| Unknown | 2 | (0.1%) | 21 | (0.0%) | ||
| Chemotherapy | <0.001 | |||||
| Yes | 1,134 | (61.0%) | 34,070 | (67.7%) | ||
| No/Unknown | 726 | (39.0%) | 16,252 | (32.3%) | ||
| Insurance | 0.002 | |||||
| Yes | 1,328 | (71.4%) | 35,881 | (71.3%) | ||
| No | 32 | (1.7%) | 1,553 | (3.1%) | ||
| Unknown | 500 | (26.9%) | 12,888 | (25.6%) | ||
| Marital status | 0.756 | |||||
| Married | 901 | (48.4%) | 24,767 | (49.2%) | ||
| Unmarried | 874 | (47.0%) | 23,373 | (46.4%) | ||
| Unknown | 85 | (4.6%) | 2,182 | (4.3%) | ||
Abbreviation: AI/AN, American Indian/Alaska Native; AP, Asian or Pacific Islander; CA-125, Cancer Antigen 125; Grade: I, well differentiated; II, moderately differentiated; III, poorly differentiated; IV, undifferentiated; V, unknown.